SCHEMBL10356249

SCHEMBL10356249

CN(CCCOc1ccccc1C#N)c1nc(Cl)nc2c1CCC2c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GBA1 P04062 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PIN1 Q13526 2/20 0.34
HTR1A P08908 2/20 0.33
HTR7 P34969 1/20 0.33
ALDH1A1 P00352 2/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
MAOA P21397 1/20 0.32
HTR2B P41595 1/20 0.32
HTR1B P28222 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360838 0.86 PIN1 (0.34) MEN1KMT2AGBA1PSEN1PSEN2
SCHEMBL10355731 0.80 PSEN1 (0.40) GBA1PSEN1PSEN2APH1BNCSTN
SCHEMBL10356082 0.80 KDM4E (0.39) MEN1KMT2APSEN1PSEN2APH1B
SCHEMBL10352854 0.78 GBA1 (0.32) GBA1UGT1A1KCNH2SLCO1B1PPARD
SCHEMBL512978 0.76 UGT1A1 (0.34) GBA1KDM4EALDH1A1UGT1A1KCNH2
SCHEMBL369451 0.75 UGT1A1 (0.48) GBA1PSEN1PSEN2APH1BNCSTN
SCHEMBL361153 0.75 GBA1 (0.34) GBA1UGT1A1KCNH2SLCO1B1
SCHEMBL10356028 0.74 PPARD (0.31) PPARDPPARA
SCHEMBL512227 0.74 HRH4 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL10258090 0.74 HRH4 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637523-B2 Compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-28 US disclosed
US-20120184565-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184565-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP MEN1 2689/4885KMT2A 4694/4885GBA1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.